Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of DHP107, a Novel Oral Paclitaxel Formulation, to Determine Maximum Tolerated Dose and Recommended Dose for Phase II Trial in Patients With Advanced Solid Cancer

NCT02890511 is registered in ClinicalTrials.gov with Daehwa Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02890511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02890511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of DHP107, a Novel Oral Paclitaxel Formulation, to Determine Maximum Tolerated Dose and Recommended Dose for Phase II Trial in Patients With Advanced Solid Cancer
Lead sponsor
Daehwa Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2010
Completion date
October 31, 2012
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, stage iv gastric cancer